Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
By A. Porsteinsson, R.S. Isaacson, S. Knox, M. Sabbagh, I. Rubino. The journal of prevention of Alzheimer's disease, 2021
633 citations recorded by the source corpus.
Alzheimer’s disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer’s disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impairment and then Alzheimer’s disease dementia. Recently, clinicians have been encouraged to diagnose Alzheimer’s earlier, before patients have progressed to Alzheimer’s disease dementia. The early and accurate detection of Alzheimer’s disease-associated symptoms and underlying disease pathology by clinicians is fundamental for the screening, diagnosis, and subsequent management of Alzheimer’s disease patients. It also enables patients and their caregivers to plan for the future and make appropriate lifestyle changes that could help maintain their quality of life for longer. Unfortunately, detecting early-stage Alzheimer’s disease in clinical practice can be challenging and is hindered by several barriers including constraints on clinicians’ time, difficulty accurately diagnosing Alzheimer’s pathology, and that patients and healthcare providers often dismiss symptoms as part of the normal aging process. As the prevalence of this disease continues to grow, the current model for Alzheimer’s disease diagnosis and patient management will need to evolve to integrate care across clinical disciplines and the disease continuum, beginning with primary care. This review summarizes the importance of establishing an early diagnosis of Alzheimer’s disease, related practical ‘how-to’ guidance and considerations, and tools that can be used by healthcare providers throughout the diagnostic journey.
Subfields: Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/b32d9cbbcddf16a7e870e7af7a554ef9500f8bfe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Jiaxing Wang
- Yilin Xia
- Lei Chen
- Jiaxian Zhang
- Yinglu Zhang
- Jifa Zhang
Citations in the corpus
- Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, background): “4,20,21 Therefore, it ’ s crucial to concentrate on the preclinical and MCI stages, where early intervention and management of modi fi able risk factors could potentially lower the risk of onset or delay the progression of disease.”
- Nanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease (2025, unknown): “As a result, early management is challenging because conventional diagnostic techniques frequently miss the disease in its early stages [46].”